Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Open
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverTNXP
HealthcareNMSUSD

Tonix Pharmaceuticals Holding Corp.

$0012345678900123456789.0012345678900123456789+3.2%
52w low (est.) $7.72$13.29 52w high (est.)
Market data · updated 1h ago
Market data
Market cap
USD175.03M
52w range
USD9.81 - USD69.97
Beta
1.65
Sector
Healthcare
Data quality
83/100
Valuation
DCF fair value
USD15.99
Margin of safety
+56.8%
Quality & efficiency
Moat score
40/100
Return on equity
-72.3%
Debt / equity
0.01
Growth & analysts
Revenue growth
+183.2%
Analyst target
USD42.20
Target upside
+313.7%
Analysts
5
Run the 10-point checklist before you buy How these numbers are made

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

Valuation

ValueGrowthProfitHealthIncome62QUALITY
Overall Rating
57
Buy
Buy

Derived from filed metrics · High confidence (83% of the inputs available)

Moat Score40
DCF Intrinsic Value
USD15.99+56.8% upside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
USD175.03M
P/E Ratio
N/A
Dividend Yield
0.00%
Revenue Growth
+183.2%
Profit Margin
0.0%
ROE
-72.3%
Debt / Equity
0.01
Beta
1.65
High GrowthBeaten Down
vs Healthcare sector:Moat 40 vs 7Yield 0.00% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · TNXP